INTRODUCTION
Strategies for managing peritoneal carcinomatosis have fundamentally changed over the past 15 years. Research into tumor spreading has shown, indeed, that development of malignant cell implants on the peritoneal layer is a more efficient process than hematogenous spread, possibly because the peritoneum is a more favorable host than other organs for tumor proliferation [1] . Hence peritoneal spread can develop without distant metastasis. These observations are consistent with the clinical finding that in as many as 30% of patients with colorectal adenocarcinoma disease progression eventually leads to synchronous (8-10%) or metachronous colorectal peritoneal carcinomatosis (25%) [2, 3] . The concept has, therefore, emerged that since some peritoneal carcinomatosis, including those of colorectal origin, are a form of locoregional cancer dissemination, they should be treated with a locoregional approach [4] .
An aggressive locoregional approach, including peritonectomy procedures (cytoreductive surgery-CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has effectively altered the history of colorectal peritoneal carcinomatosis. Median survival rates are approaching 2 years along with long-term survival ranging from about 22% to 49% [5] [6] [7] .
This combined treatment approach is nevertheless costly, time-consuming, and carries high morbidity and mortality rates that come within acceptable ranges only after a lengthy learning curve [8] [9] .
Ample evidence [7, 10] now shows that the therapeutic index for integrated treatment closely depends on patient selection, a criterion which is currently assessed by clinical and quantitative prognostic indicators, based on the extent of peritoneal disease and likelihood of achieving complete or optimal cytoreduction. Hence selecting patients with less extensive carcinomatosis and with a higher likelihood of achieving complete cytoreduction would presumably increase survival rates for treated patients and at the same time reduce the rates of surgical complications. On the other hand, using excessively strict patient selection criteria might lead to underestimate patients that might be cured, leaving them untreated and without other alternative therapeutic options. Inappropriate patient selection therefore remains a major concern.
In this study we prospectively collected clinical data for a consecutive series of 146 patients with colorectal peritoneal carcinomatosis who underwent cytoreductive surgery combined with HIPEC in order to investigate whether currently used criteria appropriately select candidates for such treatment procedure.
PATIENTS AND METHODS

Patients
Preoperative, operative and follow-up data on 146 consecutive patients, presenting with peritoneal carcinomatosis of colorectal origin and treated by surgical cytoreduction combined with HIPEC in 5 Italian Hospital and University centers, were entered into a database over a period from April 1995 to April 2007. The study began in two centers and then, in more recent years, three other joined them. Patients' characteristics are summarized in Table 1 .
Clinical and surgical records, diagnostic imaging, laboratory and pathology reports were prospectively entered into the database and regularly updated according to a study protocol designed in the 1990s for the Italian Society of Locoregional Cancer Therapies in Oncology (CCR) score. The PCI was evaluated intraoperatively to quantify the extent of disease as a numerical score (0-39). The CCR score is an index that quantifies the extent of residual disease in four categories: CCR0 is no residual macroscopic disease; CCR1 is residual tumor less than 2.5 mm; CCR2 is residual tumor between 2.5 mm and 2.5 cm, and CCR3 is residual tumor more than 2.5 cm or confluent nodules [11] . 
Surgical procedure and HIPEC
Cytoreductive surgery consisted of the major peritonectomy procedures proposed by Sugarbaker [12] and reappraised by SITILO [11] [12] [13] [14] .
Patients with CCR0-1 were further subjected to HIPEC. The choice of perfusion modality (open, semi-closed or closed techniques) was left to the operator's discretion. To continuously monitor peritoneal temperature, thermocouples were placed in most regions of the abdominal cavity. During perfusion, a heat exchanger kept the perfusate at approximately 45°C thus maintaining the intracavitary perfusate at 41.5°C-43°C, i.e., a temperature range previously shown to act synergically with the antiblastic drugs used, while maintaining regional toxicity at acceptable levels [15] . Over the 12-year study the drugs perfused were cisplatinum (25 mg/m 2 /l of perfusate), or cisplatinum (25 mg/m 2 /l) plus mitomycin-C (3.3 mg/m 2 /l), and perfusion lasted 60-90 minutes. A group of 11 patients treated more recently (2005) (2006) (2007) according to the Elias protocol [16] received HIPEC with oxaliplatin perfused at a dose of 460 mg/m 2 in 2 l/m 2 of 5% dextrose at a temperature of 42-44°C over 30 min and intravenous administration of 5-FU (400 mg/ m 2 ) and leucovorin (20 mg/m 2 ).
The choice of constructing an ileostomy was left to the individual surgeon's discretion.
All patients were admitted to the postoperative intensive care unit (ICU) for at least 24 hours.
Clinical data were recorded on a standard database form and evaluated by a single investigator. Systemic toxicity was defined according to the World Health Organization (WHO) criteria. Locoregional HIPEC-related toxicity was scored according to a modified Ozols classification. [17] . Median follow-up was calculated from the date of surgery to last follow-up assessment or death.
Statistical analysis
Differences in rates were tested by chi-square or Fisher's exact test according to sample size.
Survival was analyzed with Kaplan-Meier's method and the log-rank test was used to compare survival curves. Standard probability cut-off, P≤ .05, was chosen as significance level. Cox proportional-hazards model was used to investigate the role of prognostic factors in outcome and P-values< .10 were considered significant. Data were analyzed using the Statistical Package for Social Sciences (SPSS Inc., Chicago, IL), version 11.0.
RESULTS
Combined treatment and complications
Upon admittance 11% of the patients had symptoms of bowel occlusion and 6.2% had a history of previously resected liver metastases or liver metastases synchronous with peritoneal carcinomatosis. Seventy-six percent of the patients had undergone previous surgery, mostly for primary adenocarcinoma and 68% had already received systemic chemotherapy either as adjuvant or as palliative treatment with 5-fluorouracil and leucovorin or, less frequently, with cisplatin, mitomycin-C, oxaliplatin and irinotecan singly or combined with other antineoplastic drugs. In 49% of the patients the PCI ranged from 10 to 20, whereas in 18% PCI exceeded 20.
Total peritonectomy was required in 25% of the patients. Complete cytoreduction (CCR score 0) was achieved in 851% and optimal cytoreduction (CCR score 1) in 7.5% of the cases. In The postoperative mortality rate was 2.7%.
Follow-up data and survival analysis
When we assessed oncologic outcome in the 146 patients, at a median follow-up of 19 months (ranging from 1 to 108 months), the 2-year overall survival rate was 45% with a median survival of 21 months, whereas the 2-year disease-free survival rate was 33%, decreasing to 26% in the 3 rd year (Fig. 1) .
No difference was found in survival rates for patients with synchronous or metachronous carcinomatosis or survival in relation to site of the primary tumor. Furthermore, disease-free interval elapsing between resection for the primary adenocarcinoma and the onset of peritoneal carcinomatosis was not related to survival. No significant difference in survival was observed for a disease-free interval (DFI) below or above the 24-month cut-off (median survival 21 vs 25 months). Median survival differed, though not significantly, according to the HIPEC technique used: it was longer for closed perfusion than for open perfusion (22 months vs. 17 months; P= .08). Median survival was longer in patients treated with oxaliplatin compared to the overall series (28 vs. 21 months) ( Fig. 2) , but the small sample size prevented us from analyzing the statistical significance of the difference.
Analysis of the association between the Sugarbaker PCI for staging peritoneal malignancies
and survival showed that median survival diminished as the PCI increased (23 months in patients with a PCI lower than 11, 16 months in those with a PCI between 11 and 20, and 11 months in those with a PCI greater than 20 (P = .06). When we excluded from the analysis the data for the seven patients with liver metastases resected during peritonectomy or previously at the onset of carcinomatosis, the differences in median survival rates became statistically significant (PCI<11: 31 months; PCI 11-20: 19 months and PCI> 20: 14 months; P= .01 by chi-square test). The presence of liver metastases, resected at any time during the course of disease had a significant unfavorable prognostic influence on median survival, which decreased from 22 months in patients with no liver metastases to 6 months in patients with liver metastases (P < .001).
Disease distribution was retrospectively assessed (at the time of analysis looking at the operative notes) in relation to survival, considering as "unfavorable sites" those deemed to make complete surgical cytoreduction unlikely, such as small bowel mesenteric implants, disease extensively involving the porta hepatis or the diaphragm as well as bulky upper retroperitoneal lymph nodes. Disease involving unfavorable sites significantly worsened the prognosis (median 23 vs. 14 months; P =.003 by Fisher's test).
CCR score strongly correlated with survival. Indeed, the 2-year survival in patients with no macroscopic residual disease (CCR-0) was 50 % (median survival 25 months). Conversely, patients with residual disease lower than 2.5 mm (CCR-1) had a 10% survival rate (median survival 11 months) and patients with residual disease greater than 2.5 mm (CCR 2-3) after peritonectomy had no 2-year survivors (median survival 8 months) (P=.0001) ( Fig. 3) .
Cox proportional-hazards model was finally used to investigate the independent value of all above mentioned prognostic factors. When all the variables that reached statistical significance on the log-rank test were tested by multivariate analysis they all independently affected patients' survival ( Table 2) .
DISCUSSION
Our median overall survival rate of 21 months compares well with published survival rates from similar series [18] [19] [20] and increases to 25 months in patients in whom cytoreductive surgery left no residual macroscopic disease. Contrary to expectations, median survival increased less accordingly to the completeness of cytoreduction in our series than in others [10, 19, 20] , probably depending on a subgroup of approximately 40 patients with widespread carcinomatosis enrolled in the early years of the study. These patients, in fact, had an unfavorable prognosis, despite cytoreductive surgery almost invariably achieved macroscopically complete cytoreduction.
The observed mortality rate of 2.7%, due to 10% of patients who developed major complications, matches the rate for advanced cancer surgery. However, the possible advantages of an ileostomy in managing complications after cytoreductive surgery combined with HIPEC remain controversial.
When we investigated variables that might help improving patient selection, thus optimizing the oncologic outcome, we found no correlation between certain clinical and pathologic indicators such as age, performance status or tumor grade with survival. Both site of primary colorectal tumor and the presence of synchronous or metachronous carcinomatosis failed to correlate with survival. Moreover, we did not show an increased incidence of surgical failure in patients with symptoms of intestinal partial occlusion, since in almost 80% of the cases cytoreductive surgery achieved CCR-0. The feasibility of optimal cytoreduction was among the few selection criteria applied in the early years of the study. Hence, patients with extensive small bowel involvement were only occasionally included in this treatment group.
Even though DFI is a major prognostic factor in many malignant diseases, and also in colorectal cancer, it has never been considered a prognostic factor of importance in selecting patients with carcinomatosis. In our series, we found an interesting (though not significant) difference between patients categorized on the basis of a 24-month DFI (21 vs. 25 months), which is in agreement with other studies showing a significant correlation between DFI and survival in patients with recurrent peritoneal carcinomatosis of colorectal origin after combined treatment [21] . In this setting, DFI seems a major prognostic factor in predicting outcome.
The Sugarbaker PCI for staging peritoneal malignancies provides no information on the tumor's metastatic potential or probable response to treatment. The lack of suitable biomolecular markers partly nullifies the currently used selection criteria and explains why the recent Consensus Conference failed to establish precise PCI values to use as a cut-off [22] .
The prognostic variable that had the major influence on survival in our series, namely the completeness of cytoreduction, can be reliably assessed only at the end of surgical treatment.
In any case, bulky residual tumor should always be avoided and the surgeon should probably stop, if is possible, once it is recognized that a CCR0-1 is not feasible.
The difference in biological aggressiveness might well explain our survival results in relationship to the site of disease. At first glance, they suggest that malignant foci that are hard to eradicate correlate with surgical failure. In practice, however, if the problem concerned only the possibility of achieving complete cytoreduction, the risk related to site should have no independent prognostic ability in the multivariate analysis and would carry less statistical weight than the completeness of cytoreduction. An alternative explanation is that some disease locations can themselves reflect aggressive behavior, their prognostic value remaining even after macroscopic tumor resection. This hypothesis is in agreement with Sugarbaker's distribution theory that tumor aggression levels differ according to the characteristics of the malignancy [23] .
A finding that invites further investigation concerns the choice of the HIPEC technique to be used, given that survival was substantial different between patients treated with open, semiclosed or closed abdomen HIPEC. We speculate that since closed HIPEC leads to lower heat dispersion it induces greater toxicity and is possibly more effective than the other modalities. In a study conducted by our group at the National Cancer Institute Regina Elena in Rome in the late 1990s, we evaluated the thermal doses (heat delivered in a unit of time) An especially promising antineoplastic drug that became available for HIPEC perfusion over the 12 years we reviewed is oxaliplatin. Our preliminary oxaliplatin-induced survival rate of 28 months is an extremely encouraging finding. Oxaliplatin is the most active drug as a single agent in adjuvant chemotherapy for colorectal adenocarcinoma and in metastatic disease and induces its antineoplastic effects independently from cell-cycle phases, acting synergically with hyperthermia [24] . In recently published study conducted on a series of 48 patients with colorectal carcinomatosis treated with surgical cytoreduction plus HIPEC with oxaliplatin [25] and comparing a similar number of patients, homogeneous for disease, age and performance status, treated with palliative chemiotherapy, the 5-year overall survival rate was 51% for the HIPEC group and only 13% for the palliated group.
While the currently used criteria for selecting patients with colorectal peritoneal carcinomatosis to undergo combined treatment rely mainly on disease staging, the main future
CONCLUSIONS
In conclusion, careful patient selection allows a high rate of complete cytoreduction.
Combined with HIPEC, complete cytoreduction results in a median survival rate of about 21 months in patients with extensive colorectal carcinomatosis. The slight treatment benefit from combined management in patients in whom surgery achieves optimal cytoreduction (CCR-1) should increase as new chemotherapy regimens for perfusion come into more widespread use.
The therapeutic index should also substantially improve as research identifies more effective criteria for selecting patients increasingly based upon the biomolecular features of carcinomatosis. Meanwhile, patient selection could be improved by assigning patients a preoperative score based on the independent prognostic variables identified in the multivariate analysis. 
